Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Frontline strategies for “low-risk” and prefibrotic myelofibrosis: when to treat?

Alexander Coltoff, MD, Medical University of South Carolina Hollings Cancer Center, Charleston, SC, presents on frontline treatment strategies and the timing of intervention for patients with “low-risk” or prefibrotic myelofibrosis (MF). Dr Coltoff highlights results from a Phase II study (NCT04988815) of ropeginterferon alfa-2b and the ongoing Phase III HOPE-PMF trial (NCT06468033). He also highlights the need for improved patient selection and consensus on therapeutic goals. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

All right, thanks so much. So I think we’ve heard a lot about emerging strategies today, novel strategies that are being developed. And as we get more and more strategies, and more and more hopefully potentially disease-modifying strategies, I think it’s important to just consider what patient population we’re really targeting with treatment.

Let’s see. My disclosures...

All right, thanks so much. So I think we’ve heard a lot about emerging strategies today, novel strategies that are being developed. And as we get more and more strategies, and more and more hopefully potentially disease-modifying strategies, I think it’s important to just consider what patient population we’re really targeting with treatment.

Let’s see. My disclosures.

Just to tie it into the talks we’ve heard so far in this session about combination strategies, I thought I would just point out that a lot of the patients in the current clinical trial space for myelofibrosis really do fall more into that intermediate-1 or maybe less advanced cohort of patients than those with very high-risk or high-risk disease. And if you actually look at the data, a lot of the patients who derive some benefit from the combination strategies we’ve talked about here do fall into the intermediate-1 risk subgroups. You can see at least numerically slightly improved outcomes in the intermediate-1 patients compared to those with more high-risk disease throughout the MANIFEST and MANIFEST-2 data, the earlier navitoclax data, and then the selinexor data.

I think this is something that we touched on a little bit in an earlier session, but when we were talking about when to intervene for patients with low-risk or prefibrotic myelofibrosis, or even high-risk JAK2 CHIP, I think it’s always based on a balancing of the risks and rewards of treatment. And at least, I think, 10, 15 years ago, when we did not know too much about the VAF reduction capabilities or disease modification capabilities of either older therapies, or before we had more novel therapies, I think a lot of the balance was skewed towards observation for patients with low-risk or prefibrotic myelofibrosis. There are drug toxicities. There’s turning, quote-unquote, healthy or normal people into patients. There’s the cost of these drugs. There’s increased healthcare expenditure. And with our old armamentarium of ruxolitinib and other earlier JAK inhibitors, I think we saw SVR improvements and TSS improvements, but those were maybe not enough to tip the scales into intervening earlier on.

With those same downsides in mind of starting treatment earlier, I think we’re looking at more novel endpoints, or more incentives, to potentially start patients on therapies earlier, right? So besides just spleen volume reduction or symptom improvement, we might consider decreases in driver allele burden, decreases in co-mutational, higher-risk mutational burdens, fibrosis reversal, and then I think the ultimate goal of treatment, really, survival benefits with overall survival or progression-free survival.

To this end, I think the most developed trials in this space so far come from the use of ropeginterferon alfa-2b in the prefibrotic myelofibrosis space. So this is the result of a Phase II study published earlier this year. The study enrolled around 70 patients with either prefibrotic myelofibrosis or intermediate-1 risk myelofibrosis, who had some indication for cytoreduction, either disease-related symptoms, thrombocytosis or leukocytosis. And all patients were treated with ropeginterferon at the escalated dosing schema you see there. The majority of patients in the study actually had prefibrotic myelofibrosis, about three-quarters, and the remainder had either low- or intermediate-1 risk MF. The clinical and hematological response was met quite frequently by patients in the study, but that’s probably not the most compelling or interesting aspect of the results, I think.

Investigators also reported on the outcomes of bone marrow fibrosis and variant allele frequency reduction. So for patients with data available at 48 weeks, marrow fibrosis was reduced in 22% of patients and increased in 10% of patients. And then, as we see here on the graphs, there’s the reduction in the JAK2 and the CALR variant allele burden over time. You can see with the JAK2 group at the top, which is considerably more patients, starting at around week 24 to 28, you see a statistically significant decrease in the JAK2 median VAF at basically almost every time point as we continue on treatment. The CALR group, as prior studies would have maybe hinted at, had a less robust reduction in the variant allele frequency, but still met a statistically significant reduction by the last time point reported. No cases of disease acceleration, development of leukemia, thrombosis or hemorrhage were observed in the study period, but it should be noted that this is a relatively short follow-up, with a patient population that’s not expected to have a very quick time to progression or to these events.

There’s the ongoing HOPE-PMF study that I think most people are aware of. I believe accrual is closed for that. That’s a randomized trial looking at ropeginterferon versus placebo in patients with a very similar kind of background to the Phase II study we just looked at: so prefibrotic MF or early-stage MF, and then ineligible for a JAK inhibitor at screening. It’ll be interesting to see these results as well.

I will say, I think MPNs in general have lagged behind a little bit compared to other spaces in hematologic malignancies. I’m not saying I necessarily agree with all of these studies, but there is definitely more of a push to intervene earlier, sometimes fairly aggressively, in some other conditions. So for MGUS, for example, we have some low-risk intervention studies looking at things like rifaximin. For MGUS, we also have some fairly, I would say, maybe controversial or just thought-provoking studies looking at things like bispecifics, or potentially more toxicity-associated therapeutics, in the earlier plasma cell space. We have ivosidenib, we’ve got enasidenib, we’ve got targeted therapies for high-risk CCUS nowadays, some of which have been reported at ASH and other conferences. We’ve looked at earlier intervention for low-risk MDS with a number of agents. There actually is an investigator-initiated trial, I believe, now in Boston, looking at ropeginterferon for high-risk JAK2 clonal hematopoiesis, looking at monthly ropeg dosing in that patient population.

I think this really just highlights the major discussion around when to intervene in the spectrum from JAK2 CHIP all the way to accelerated and blast phase. So as time has gone on and older studies have read out and had longer follow-up, we’ve seen evidence of, if not disease modification, at least significant reductions in driver allele burdens, and associated reductions in things like progression-free and myelofibrosis-free survival, with some of our ropeginterferon studies, interferon studies, as well as some of the ruxolitinib data from MAJIC-PV.

I think as we get towards the more advanced stages of MPNs, your accelerated and blast phase, even high-risk DIPSS or high-risk MIPSS, I think we’re all still pretty comfortable saying that transplantation is really the only true disease modification that we have available in 2026. Though we’ll see how the longer readouts from some of the Phase III studies described earlier in the session go. And with the novel therapeutics like the type II JAK inhibitors, and some other in-development studies, we’ll see if we can intervene at that stage. I think really more data is needed here. And I’d be lying if I said I knew the right answer for these patients, but I certainly hope that with more targeted therapeutics and safer therapeutics, we can maybe turn this space into more of the PV/ET space.

How can we increase feasibility quickly? I think there are a lot of options, and they’re not all easy, but I think they’re worth considering. We can delineate patients until the cows come home, but there are definitely some low-risk patients who unfortunately don’t follow that low-risk expected timeline. And so I think just better molecular, better… maybe AI will help us, but better delineation of which patients are more likely to benefit from earlier intervention. I think consensus with MPN experts in terms of what our goals are for treating low-risk or prefibrotic MF would be helpful. Incorporating lessons from prior attempts like ReTHINK, in terms of intervening earlier, potentially using strategies like decentralized studies or working with the cooperative group networks to increase feasibility of studies, could be important as well.

And with one second left, this is just the general overview of treatment options in 2026. Thanks for your time.

AI-generated transcript. Please refer to the video as the authoritative source.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.